Xarelto lawsuits alleging patients suffered severe bleeding events after using the anticoagulant drug are gaining momentum, with over 2,000 lawsuits awaiting courts to listen. Accusers claim they were not warned Xarelto had no antidote and were not warned about the risks of a serious bleeding event while using the drug.
As of December 15, 2015, there were 2,400 lawsuits merged for pretrial proceedings in MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before US District Judge Eldon E. Fallon) according to reports from the Judicial Panel for Multidistrict Litigation (JPML). While the growth of the MDL has slowed down somewhat from October, there is still a substantial number of lawsuits added to the MDL every month. Up to 2,266 lawsuits were consolidated as of November 16, 2015, which was up from the 1,698 lawsuits consolidated by mid-October.
Lawsuits claims users were not warned that Xarelto, unlike Coumadin, did not contain an antidote to the medication’s anticlotting property. Xarelto is an anticoagulant, used to lessen the risk of blood clots and strokes. However it, like its precursor Coumadin, is related with an augmented risk of serious bleeding events due to its anticlotting mechanism.
Having been in the markets for decades, Coumadin has an antidote in the form of vitamin K. Users who suffered a bleeding event and received medical care in time could end the adverse condition. However, individuals using newer anticoagulants such as Xarelto, presently have no recognized antidote. That means if they suffer a bleeding event, they have to wait for the drug to leave their system. Appellants claim that they wouldn’t have used Xarelto if they had known it didn’t have an antidote.
The first bellwether trials in the Xarelto lawsuit are not expected to go to court until early 2017. In a case management order (11/30/15), Judge Fallon noted that the two sides could not resolve differences regarding discovery pool appellants and bellwether trial appellants, and gave out orders about how cases could be carefully chosen for inclusion in the discovery pool. The judge also noted that four cases will be chosen as bellwether cases but did not issue an order on choosing bellwether trial cases.
Janssen Pharmaceuticals who manufactured Xarelto, maintains the medication is not perversely perilous and the warnings given on the drug usage are sufficient.